

In the Claims

Prior to calculating the filing fees, please cancel claims 30-33 without prejudice to their subsequent reintroduction into this application or their introduction into a subsequently filed continuation application.

REMARKS

Upon entry of this amendment, claims 1-29 are pending. Applicants have cancelled claims 30-33 without prejudice and without any intention of abandoning the subject matter therein. Applicants submit that no new matter is introduced by these amendments.

Applicants have amended the specification so as to enter appropriate sequence identifiers for each of the sequences in Table 2. In addition, Applicants have also amended Table 2 to attend to typographical errors. The fourth sequence for TGF beta 2 ends with "MTP," which is intended to identify the next group of three sequences in the table. The three sequences, now identified as corresponding to SEQ ID NOS: 33, 34, and 35, are well known MTP sequences such that one skilled in the art would realize that the error in Table 2 as originally filed was, in fact, typographical in nature. In addition, the CD44 sequence (corresponding to SEQ ID NO: 1), the first HOX 2.5 sequence (corresponding to SEQ ID NO: 5), the second Integrin Beta sequence (corresponding to SEQ ID NO: 26), the second CTCF sequence (corresponding to SEQ ID NO: 28) and the first MTP sequence (corresponding to SEQ ID NO: 33) have been amended to correct typographical errors. Each of these sequences are well known sequences such that one skilled in the art would realize that the errors in Table 2 as originally filed, were, in fact, typographical in nature. Applicants submit that no new matter is introduced by these amendments.


CONCLUSION

Applicants respectfully submit that all of the pending claims are in condition for allowance and request early favorable action.

Respectfully submitted,

• Date: July 29, 2003
• Reg. No.: 43,153

Tel. No. (617) 310-8168
Fax No. (617) 790-7100



Diana M. Steel
Attorney for Applicants
Testa, Hurwitz, & Thibeault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110

MARKED-UP VERSION OF AMENDED SPECIFICATION

TABLE 2

Gene	#'UTR Consensus Sequence
CD44	<u>AUUUUCUAUCCUUU</u> <u>UUUAUUUUAUGUCAUUUUUUUA</u> [SEQ ID NO: 1] UAAAAAACCAAA <u>UUUGAUU</u> GGCUCUAAACA [SEQ ID NO: 2]
IGF-2	UAAAGAA <u>AUUAUU</u> GGCUAAAAACAUA [SEQ ID NO: 3] CUAAAA <u>AUUAUU</u> GGCUAAAAAA [SEQ ID NO: 4] UCACUCUU <u>UUAUUUU</u> AU [SEQ ID NO: 5]
HOX 2.5	AAAU <u>UUUAUUA</u> AGUUA [SEQ ID NO: 6] AUCAGG <u>UUCAUUU</u> UGGUUGU [SEQ ID NO: 7]
Inhibitor J6	AU <u>UUUAUCU</u> GUUA [SEQ ID NO: 8] UUUUGUUUUUCUCCCUUUU <u>UUAGUUU</u> UUUCAA [SEQ ID NO: 9]
GADD45	UAUUUUUUUUCUUUUUUUU <u>UUUUGGU</u> CUUUAU [SEQ ID NO: 10] UUAUAUUCUCAGAAGU <u>UUUAUU</u> AUAAUCUU [SEQ ID NO: 11] UUCUGUAAAUAUU <u>UUUAUAU</u> ACUGCUUUCUUUUU [SEQ ID NO: 12]
Nexin 1	AUUUUAUAGUAGUU <u>UUUAUGU</u> UUUUAUGGAAAA [SEQ ID NO: 13] AUUUGCCUU <u>UUUAAUU</u> CUUUUU [SEQ ID NO: 14]
Egr-1	UAUUUUGUGGU <u>UUUAUUU</u> UACUUUGUACUU [SEQ ID NO: 15]
Zif268	U <u>UUUGUUU</u> UCCUU [SEQ ID NO: 16] UUU <u>UUUAUUU</u> UCUGUAUUUUUU [SEQ ID NO: 17]
Neuronal- Cadherin	UUUUUUUUAAAUUUU <u>UUUAUUU</u> UCUUUU [SEQ ID NO: 18] UUUUUUAUUUUC <u>UGUAUUU</u> UUU [SEQ ID NO: 19] UUUUUAAUUU <u>UUUAAUU</u> UUUUUU [SEQ ID NO: 20]
Integrin alpha 5	AAUGG <u>UUUAUAU</u> UUAUGAU [SEQ ID NO: 21] UUG <u>UUUAUAU</u> CUUCAU [SEQ ID NO: 22]
SEF2	UUCAAGCGC <u>UGANUU</u> [SEQ ID NO: 23]
Cf2r	UGCAUCGAUCCG <u>UGAUUUU</u> ACUACU [SEQ ID NO: 24]
Integrin Beta	UAUAAUUU <u>UUAAUUU</u> UUUUAUUUUU [SEQ ID NO: 25] UUAUUUUACCUUUUUUUUUUUC <u>UUUAAUU</u> CCUGGU [SEQ ID NO: 26]
CTCF	UUAUGAAUGU <u>UAUAUUU</u> GU [SEQ ID NO: 27] UC <u>UUAAUUU</u> UUUCUUUUUUUUUCUUU [SEQ ID NO: 28] UUUUUUUUUCCU <u>UUUAAUU</u> GUAAAUGGUUCUUU [SEQ ID NO: 29]
TGF beta 2	UUAAGAUCAUUCAGAUUGUA <u>UAUAUUU</u> GUUCCUUU [SEQ ID NO: 30] UUCAAUUUUU <u>UUUAUAU</u> ACUAUCUU [SEQ ID NO: 31] UUUUUC-- <u>UUUAAUU</u> GGUUUUUUU[MTP-----] [SEQ ID NO: 32]
MTP	UGUCUUGU[T]CUGAGCA <u>UUUAUUU</u> UCAA [SEQ ID NO: 33] UUCUCGUCUUG <u>UUUAUUU</u> UACAA [SEQ ID NO: 34] UAUAUAUAUAG <u>UUUAUGU</u> UUUUGGAUGUUUGGU [SEQ ID NO: 35]
Cyclin D2	AUGUCUUGUUCUU <u>UGUGUUU</u> UUAGGAU [SEQ ID NO: 36] (AU/GA) <u>UUUAUUU</u> (UA/AG) [SEQ ID NO: 37]
<i>In Vitro Consensus Sequence</i>	